MapLight Therapeutics, Inc. (MPLT) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$11.21

From 52W high−72.56%

Volume1.67M

Market cap$506.45M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$11.21

From 52W high

−72.56%

Volume

1.67M

Market cap

$506.45M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.9x

P/E (TTM)

—

RSI (14)

31.1

MomentumView details →

1D Return

−3.53%

YTD Return

−38.56%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.9x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

1.5x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−65.99%

ROA (TTM)

−62.39%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

−72.69%

Revenue CAGR 3Y

—

EPS CAGR 3Y

−95.72%

EBITDA YoY

—

MomentumView details →

1D Return

−3.53%

YTD Return

−38.56%

1Y Return

—

RSI (14)

31.1

vs 50D SMA

−39.54%

vs 200D SMA

−50.75%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

16.52x

Quick Ratio

16.52x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.32

EPS Surprise

2.15%

Beats (12Q)

1/12

Next Q EPS Est

−$1.18

Avg Surprise (4Q)

−563.88%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−229.83M

Op. CF (TTM)

−174.67M

Next earningsDec 3, 2026 →

Latest newsMore news →

MapLight Therapeutics reported financial results for the second quarter ended June 30, 2026, ending the quarter with $351.3 million in cash, cash equivalents and investments.38d ago

MapLight Therapeutics reported Phase 2 IRIS results for ML-004 in autism spectrum disorder, with clinically meaningful improvements in irritability observed in a prespecified adolescent subgroup.38d ago

Similar companies

Assembly Biosciences, Inc.ASMB Contineum Therapeutics, Inc. Class A Common StockCTNM XOMA Royalty Corp.XOMA Entera Bio Ltd.ENTX Autolus Therapeutics plcAUTL Puma Biotechnology, Inc.PBYI Find similar companies →

Latest newsMore news →

MapLight Therapeutics reported financial results for the second quarter ended June 30, 2026, ending the quarter with $351.3 million in cash, cash equivalents and investments.38d ago MapLight Therapeutics reported Phase 2 IRIS results for ML-004 in autism spectrum disorder, with clinically meaningful improvements in irritability observed in a prespecified adolescent subgroup.38d ago MapLight Therapeutics announced a private placement financing (PIPE) to raise approximately $150 million in gross proceeds from institutional and accredited investors.38d ago